[HTML][HTML] New lesions detected by single nucleotide polymorphism array–based chromosomal analysis have important clinical impact in acute myeloid leukemia
Journal of clinical oncology, 2009•ncbi.nlm.nih.gov
Purpose Cytogenetics is the primary outcome predictor in acute myeloid leukemia (AML).
Metaphase cytogenetics (MC) detects an abnormal karyotype in only half of patients with
AML, however. Single nucleotide polymorphism arrays (SNP-A) can detect acquired somatic
uniparental disomy (UPD) and other cryptic defects, even in samples deemed normal by
MC. We hypothesized that SNP-A will improve detection of chromosomal defects in AML and
that this would enhance the prognostic value of MC.
Metaphase cytogenetics (MC) detects an abnormal karyotype in only half of patients with
AML, however. Single nucleotide polymorphism arrays (SNP-A) can detect acquired somatic
uniparental disomy (UPD) and other cryptic defects, even in samples deemed normal by
MC. We hypothesized that SNP-A will improve detection of chromosomal defects in AML and
that this would enhance the prognostic value of MC.
Abstract
Purpose
Cytogenetics is the primary outcome predictor in acute myeloid leukemia (AML). Metaphase cytogenetics (MC) detects an abnormal karyotype in only half of patients with AML, however. Single nucleotide polymorphism arrays (SNP-A) can detect acquired somatic uniparental disomy (UPD) and other cryptic defects, even in samples deemed normal by MC. We hypothesized that SNP-A will improve detection of chromosomal defects in AML and that this would enhance the prognostic value of MC.
ncbi.nlm.nih.gov